Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|August 6, 2009
String of attacks aimed at Novartis CEO
Author(s)Amelia Tope
Novartis has confirmed that the ashes of CEO Daniel Vasella's mother have been stolen and his holiday home set fire to.
Advertisement
Novartis has confirmed that the ashes of CEO Daniel Vasella’s mother have been stolen and his holiday home set fire to. The company believe animal rights militants to be behind the attack.
The fire, at Vasella’s lodge in Bach, Austria, was started last Monday and has been confirmed as arson. It came a week after his mother’s ashes were stolen and “Drop HLS Now” was spray painted on the grave.
Theses incidents follow a long list of recent attacks against the company. A few weeks ago threatened messages aimed at Vasella and Novartis were written on the church in Vasella’s village of Risch in central Switzerland. According to a report by
The Stop Huntington Animal Cruelty group which campaigns against animal testing at the British laboratory, Huntingdon Life Sciences, has denied any involvement in the attacks.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement